ArticleNPJ breast cancer2017
Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells.
Article in NPJ breast cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- The mechanism of breast cancer stem cells and tumor microenvironment promoting radioresistance in breast cancer and its intervention strategies.Frontiers in immunology · 2026Pooled it
- Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation.Signal transduction and targeted therapy · 2026Review
- Deep learning inference of cell type-specific gene expression from breast tumor histopathology.NPJ precision oncology · 2026Article
- A weight-sharing Bayesian neural network for consistent feature selection with applications in cancer gene expression data.BMC bioinformatics · 2026Article
- Integrated multi-omics profiling of plasma extracellular vesicles reveals the hsa-miR-1-3p-LRP1 axis as a potential biomarker in cervical cancer.Molecular and clinical oncology · 2026Article
- Etiology of polyploid giant cancer cells: a new frontier in cancer biology.Cancer cell international · 2026Review
- Dynamic modelling of cell cycle arrest through integrated single-cell and mathematical modelling approaches.PLoS computational biology · 2025Article
- Enhanced prediction of breast cancer patient response to chemotherapy by integrating deconvolved expression patterns of immune, stromal and tumor cells.bioRxiv : the preprint server for biology · 2025Article
- Small-Molecule Mitotic Inhibitors as Anticancer Agents: Discovery, Classification, Mechanisms of Action, and Clinical Trials.International journal of molecular sciences · 2025Review
- Design and synthesis of thiadiazoles as anticancer, apoptotic, and VEGFR-2 inhibitors.Future medicinal chemistry · 2025Article
- A new insight into the impact of copy number variations on cell cycle deregulation of luminal-type breast cancer.Oncology reviews · 2025Review
- Bioinformatics-Driven Investigations of Signature Biomarkers for Triple-Negative Breast Cancer.Bioinformatics and biology insights · 2025Article
- G2/M Checkpoint Modulation: Insights from miRNA Profiles in FAM and Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- NNMT/1-MNA Promote Cell-Cycle Progression of Breast Cancer by Targeting UBC12/Cullin-1-Mediated Degradation of P27 Proteins.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- The use of SP/Neurokinin-1 as a Therapeutic Target in Colon and Rectal Cancer.Current medicinal chemistry · 2024Review
- Cell cycle responses to Topoisomerase II inhibition: Molecular mechanisms and clinical implications.The Journal of cell biology · 2023Review
- Epigenetic reprogramming of cell cycle genes by ACK1 promotes breast cancer resistance to CDK4/6 inhibitor.Oncogene · 2023Article
- β-caryophyllene oxide induces apoptosis and inhibits proliferation of A549 lung cancer cells.Medical oncology (Northwood, London, England) · 2023Article
- ASGARD is A Single-cell Guided Pipeline to Aid Repurposing of Drugs.Nature communications · 2023Article
- STAT3 protects HSCs from intrinsic interferon signaling and loss of long-term blood-forming activity.bioRxiv : the preprint server for biology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Genomic instability is a hallmark of breast cancer, contributes to tumor heterogeneity, and influences chemotherapy resistance. Although Gap 2 and mitotic checkpoints are thought to prevent genomic instability, the role of these checkpoints in breast cancer is poorly understood. Here, we assess the Gap 2 and mitotic checkpoint functions of 24 breast cancer and immortalized mammary epithelial cell lines representing four of the six intrinsic molecular subtypes of breast cancer. We found that patterns of cell cycle checkpoint deregulation were associated with the intrinsic molecular subtype of breast cancer cell lines. Specifically, the luminal B and basal-like cell lines harbored two molecularly distinct Gap 2/mitosis checkpoint defects (impairment of the decatenation Gap 2 checkpoint and the spindle assembly checkpoint, respectively). All subtypes of breast cancer cell lines examined displayed aberrant DNA synthesis/Gap 2/mitosis progression and the basal-like and claudin-low cell lines exhibited increased percentages of chromatid cohesion defects. Furthermore, a decatenation Gap 2 checkpoint gene expression signature identified in the cell line panel correlated with clinical outcomes in breast cancer patients, suggesting that breast tumors may also harbor defects in decatenation Gap 2 checkpoint function. Taken together, these data imply that pharmacological targeting of signaling pathways driving these phenotypes may lead to the development of novel personalized treatment strategies for the latter two subtypes which currently lack targeted therapeutic options because of their triple negative breast cancer status.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.